DrugPatentWatch Database Preview
OLUMIANT Drug Profile
When do Olumiant patents expire, and what generic alternatives are available?
Olumiant is a drug marketed by Eli Lilly And Co and is included in one NDA. There are two patents protecting this drug.
This drug has fifty patent family members in thirty-nine countries.
The generic ingredient in OLUMIANT is baricitinib. One supplier is listed for this compound. Additional details are available on the baricitinib profile page.
Summary for OLUMIANT
| International Patents: | 50 |
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 73 |
| Patent Applications: | 32 |
| Drug Prices: | Drug price information for OLUMIANT |
| DailyMed Link: | OLUMIANT at DailyMed |
Generic Entry Opportunity Date for OLUMIANT
Generic Entry Date for OLUMIANT*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Synonyms for OLUMIANT
| (1-(Ethylsulfonyl)-3-(4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-1H-pyrazol-1-yl)azetidin-3-yl)ethanenitrile |
| 1-(Ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]-3-azetidineacetonitrile |
| 1187594-09-7 |
| 1231199-29-3 |
| 1374987-77-5 |
| 2-(3-(4-(3H-Pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(ethylsulfonyl)azetidin-3-yl)acetonitrile |
| 2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(ethylsulfonyl)azetidin-3-yl)acetonitrile |
| 2-[1-ETHYLSULFONYL-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PYRAZOL-1-YL]AZETIDIN-3-YL]ACETONITRILE |
| 3-Azetidineacetonitrile, 1-(ethylsulfonyl)-3-(4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-1H-pyrazol-1-yl)- |
| 3-AZETIDINEACETONITRILE, 1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]- |
| 3JW |
| AB0035958 |
| ABP001023 |
| AC-27404 |
| AJ-121247 |
| AKOS022186127 |
| AKOS025401933 |
| AM81232 |
| AMMD00005 |
| AOB87724 |
| AX8261519 |
| Baricitinib |
| Baricitinib (INCB28050 LY3009104) |
| Baricitinib (JAN/USAN/INN) |
| Baricitinib (LY3009104, INCB028050) |
| Baricitinib (LY3009104) |
| Baricitinib [USAN:INN] |
| BC600315 |
| BCP0726000031 |
| BCP9000380 |
| BDBM50021656 |
| C16H17N7O2S |
| CHEBI:95341 |
| CHEMBL2105759 |
| CS-0724 |
| D0Y7IC |
| D10308 |
| DB11817 |
| DS-7641 |
| DTXSID30152228 |
| EX-A413 |
| GTPL7792 |
| HMS3651L17 |
| HY-15315 |
| IN2285 |
| INCB 028050 |
| INCB 28050 |
| INCB-028050 |
| INCB-028050|||LY-3009104|||2-[1-Ethylsulfonyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile |
| INCB-28050 |
| INCB028050 |
| INCB424-ANALOGUE |
| ISP4442I3Y |
| J-503551 |
| KB-74852 |
| KS-0000044L |
| LY 3009104 |
| LY-3009104 |
| LY3009104 |
| MLS006011247 |
| MolPort-023-219-125 |
| NCGC00345839-01 |
| Olumiant (TN) |
| PB27275 |
| QCR-197 |
| RL00725 |
| S-7686 |
| s2851 |
| SC-94301 |
| SCHEMBL871150 |
| SMR004703006 |
| UNII-ISP4442I3Y |
| XUZMWHLSFXCVMG-UHFFFAOYSA-N |
| Y0439 |
| ZINC73069247 |
US Patents and Regulatory Information for OLUMIANT
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eli Lilly And Co | OLUMIANT | baricitinib | TABLET;ORAL | 207924-001 | May 31, 2018 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | Y | Y | ➤ Try a Free Trial | ||
| Eli Lilly And Co | OLUMIANT | baricitinib | TABLET;ORAL | 207924-001 | May 31, 2018 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
| Eli Lilly And Co | OLUMIANT | baricitinib | TABLET;ORAL | 207924-001 | May 31, 2018 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
International Patents for OLUMIANT
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Eurasian Patent Organization | 201071057 | ➤ Try a Free Trial |
| Serbia | 55263 | ➤ Try a Free Trial |
| Ukraine | 101493 | ➤ Try a Free Trial |
| Denmark | 2288610 | ➤ Try a Free Trial |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for OLUMIANT
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 90035-8 | Sweden | ➤ Try a Free Trial | PRODUCT NAME: BARICITINIB; REG. NO/DATE: EU/1/16/1170 20170215 |
| 2017023 | Lithuania | ➤ Try a Free Trial | PRODUCT NAME: BARICITINIBAS IR FARMACINIU POZIURIU PRIIMTINOS JO DRUSKOS; REGISTRATION NO/DATE: EU/1/16/1170 20170213 |
| 2017 00032 | Denmark | ➤ Try a Free Trial | PRODUCT NAME: BARICITINIB AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REG. NO/DATE: EU/1 /16/1170 20170215 |
| 0886 | Netherlands | ➤ Try a Free Trial | PRODUCT NAME: BARICITINIB, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/16/1170 20170215 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
